New CEO of Dexcom, Jake Leach, joined MobiHealthNews at the JPM Healthcare Conference to discuss his leadership priorities, ...

DexCom stock snapshot and recent performance DexCom (DXCM) has been drawing attention after recent price moves, with the shares last closing at $69.54. For context, the stock shows a 0.4% gain over ...

DXCM posts strong preliminary Q4 and full-year 2025 revenue growth, beating estimates, though shares slip after the ...

Having operated under a reduced capacity up to this point in the season, Connacht will finally be able to welcome supporters ...

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook ...

Supermodels, singers, and diabetics are all wearing it. Jake Leach, Dexcom CEO, says these sensors are the future.

While still a couple of years out, MD+DI gained some insights into Dexcom's next-generation sensor from an interview with the ...

Shares of medical device company DexCom (NASDAQ:DXCM) fell 2.6% in the morning session after analysts at Piper Sandler and ...

In his inaugural J.P. Morgan Healthcare Conference speech, newly minted Dexcom CEO Jake Leach looked to ease concerns over ...

On January 12, the company released its preliminary, unaudited results for Q4 2025, with total revenue coming at ~$1.260 ...

Jake Leach, Dexcom CEO, joins 'Closing Bell Overtime' to talk its 2026 outlook, the impact of GLP-1s, new devices and more.

Dexcom convinced a federal judge that its phrasing about market share in two statements about sales growth for certain ...